Cargando…
Impact of nucleos(t)ide analog treatment on the development of malignancy in patients with chronic hepatitis B
We evaluated whether nucleos(t)ide analog (NA) influences the risk of non-hepatocellular carcinoma (non-HCC) malignancies in patients with chronic hepatitis B (CHB). A total of 9867 patients with CHB were followed up for ≥12 months for the occurrence of any type of malignancy between 1998 and 2013....
Autores principales: | Kim, Soon Sun, Ahn, Eun Kyoung, Cho, Soo Yeon, Park, Rae Woong, Cho, Hyo Jung, Kim, Ji-Hyun, Kim, Han Gyeol, Lee, Ga Ram, Hwang, Sun Hyuk, Yang, Min Jae, Cheong, Jae Youn, Cho, Sung Won |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023687/ https://www.ncbi.nlm.nih.gov/pubmed/29901622 http://dx.doi.org/10.1097/MD.0000000000011087 |
Ejemplares similares
-
Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B
por: Kim, Soon Sun, et al.
Publicado: (2011) -
Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients
por: Kim, Young Jip, et al.
Publicado: (2013) -
The Molecular and Structural Basis of HBV-resistance to Nucleos(t)ide Analogs
por: Gupta, Nidhi, et al.
Publicado: (2014) -
Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients
por: Jung, Sang Kyung, et al.
Publicado: (2015) -
Gemcitabine and Nucleos(t)ide Synthesis Inhibitors Are Broad-Spectrum Antiviral Drugs that Activate Innate Immunity
por: Shin, Hye Jin, et al.
Publicado: (2018)